Physician profile
Susan E Delap
NPI 1396809919
$3,010.46
in general payments reported to CMS, 2019-2025
20 companies · $841 in 2025
The $841 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $336 · 2021: $445 · 2022: $376 · 2023: $301 · 2024: $564 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,569 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.85 |
| Education | $136.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.22 | 2021-2024 | Ubrelvy |
| Neurocrine Biosciences, INC. | $388.00 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $371.57 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $303.50 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $237.69 | 2020-2022 | |
| Pfizer INC. | $208.25 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.60 | 2022-2024 | Caplyta |
| Allergan, INC. | $175.58 | 2019-2020 | |
| Alkermes, INC. | $136.26 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $122.42 | 2024-2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $114.96 | 2023-2025 | Auvelity |
| Lundbeck LLC | $110.24 | 2020-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $92.64 | 2020-2025 | Fanapt |
| Harmony Biosciences LLC | $40.04 | 2023-2024 | Wakix |
| Biohaven Pharmaceutical Holding Company LTD. | $29.10 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25.31 | 2025 | Cobenfy |
| Eisai INC. | $15.80 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.79 | 2019 | |
| Merck Sharp & Dohme LLC | $14.23 | 2023 | Belsomra |
| Otsuka America Pharmaceutical, INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Delap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.